SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending due to escalating geopolitical tensions in the Middle East, specifically following reports of US-Israeli strikes on Iran, which is fueling intense community debate about potential oil supply disruptions, particularly through the Strait of Hormuz. Investors are sharply divided between anticipating a significant oil price spike and expecting a 'sell the news' reversal.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending amidst escalating US-Iran conflict, with strikes on Gulf infrastructure and threats to the Strait of Hormuz fueling widespread fears of global oil supply disruptions and significant crude price surges. The community is actively discussing a flight to energy assets, positioning the sector for strong momentum even as broader markets anticipate risk-off sentiment.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

The defense community is buzzing about Kratos Defense & Security Solutions, navigating a recent substantial stock offering against a wave of new contracts for its leading drone and hypersonic systems. Investors are keenly focused on the company's pivotal role in evolving global defense priorities and the anticipated surge in military spending.

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc

Aardvark Therapeutics is facing intense scrutiny and negative sentiment after voluntarily pausing its Phase 3 HERO trial for ARD-101 due to reversible cardiac safety signals observed in high-dose studies. The community is expressing significant concern about the drug's future and the company's prospects in the competitive Prader-Willi Syndrome treatment landscape.

Vanguard Group, Inc. - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending amidst heightened market uncertainty driven by Federal Reserve policy, geopolitical developments, and ongoing debates about the sustainability of valuations in the tech sector. Despite some community calls for a significant correction, many investors continue to favor VOO for its broad market exposure and long-term stability.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy is trending after solidifying its merger with Coterra Energy, a deal poised to create a new U.S. oil and gas giant with expanded production and a focus on significant shareholder returns through increased dividends and buybacks. Investors are also monitoring ongoing geopolitical tensions, which are sparking broader interest in the energy sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is a focal point of intense market and social media discussion following significant military action against Iran, including the reported death of its Supreme Leader, as investors and community members weigh the geopolitical implications and ongoing controversies.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

The $CC symbol is trending amid excitement for Canton's recent exchange listings and its Real World Asset (RWA) potential, although a significant portion of the community discussion is currently driven by "Community Coin," a charity project gaining attention for its recent donations and philanthropic model.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad (MON) is trending due to recent ecosystem integrations, including Kalshi deposits and Orbs perpetuals, coupled with a notable CNBC mention and significant institutional backing. The community is actively discussing its high-performance Layer-1 technology, attractive 12% staking yield, and perceived long-term potential as it shows resilience in a volatile crypto market.

BlackRock Institutional Trust Company N.A. - iShares U.S. Aerospace & Defense ETF

iShares Dow Jones US Aerospace & Defense

ITA is trending as intensified global conflicts, especially in the Middle East and Eastern Europe, drive community discussion around a new era of increased defense spending and military modernization. Investors are closely monitoring the sector's potential for growth, despite some mixed sentiment regarding market-specific factors and broader geopolitical implications.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aclaris Therapeutics (NASDAQ:ACRS) Announces Earnings Results, Misses Expectations By $0.01 EPS

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing...

Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference

Executives from Aclaris Therapeutics (NASDAQ:ACRS) outlined the company's clinical-stage pipeline and upcoming catalysts during a presentation at Oppenheimer's Annual Healthcare Conference...

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -9.59% and -33.04%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +5.39% and +30.48%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Corcept (CORT) delivered earnings and revenue surprises of -24.53% and -20.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics (ACRS) Projected to Post Earnings on Thursday

Aclaris Therapeutics (NASDAQ:ACRS) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have been given an average rating of "Moderate Buy" by the seven research firms that are presently covering the firm...

Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026

Aclaris Therapeutics (NASDAQ:ACRS) outlined development priorities and upcoming milestones for its biologics and oral small-molecule pipeline during a fireside chat at Guggenheim's Emerging Outlook...

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Moderate Buy" from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six analysts that are presently covering the firm, MarketBeat reports. One equities...

Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright

HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Aclaris Therapeutics in a report on Wednesday...

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Aclaris Therapeutics Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.16	--	--	N/A
Q4 '25	-$0.14	-$0.16	-10.55%	MISSED
Q3 '25	-$0.14	-$0.12	11.86%	BEAT
Q2 '25	-$0.13	-$0.13	2.15%	BEAT
Q1 '25	-$0.15	-$0.12	21.16%	BEAT

ACRS
Aclaris Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest ACRS News

ACRSAclaris Therapeutics Inc